BioCryst Pharmaceuticals’ (BCRX) In-Line Rating Reiterated at Evercore ISI

Evercore ISI restated their in-line rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Wednesday morning, MarketBeat reports. The firm currently has a $8.00 price objective on the biotechnology company’s stock.

Several other equities analysts have also commented on BCRX. Bank of America upped their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, July 1st. Wedbush upped their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $16.30.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $7.15 on Wednesday. The company has a 50-day simple moving average of $8.11 and a 200-day simple moving average of $8.70. The firm has a market capitalization of $1.50 billion, a P/E ratio of -39.72, a P/E/G ratio of 1.47 and a beta of 1.05. BioCryst Pharmaceuticals has a one year low of $6.01 and a one year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The firm’s revenue was up 49.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) EPS. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director directly owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of BCRX. Headlands Technologies LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at about $32,000. GAMMA Investing LLC lifted its holdings in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 5,449 shares during the last quarter. New Age Alpha Advisors LLC purchased a new stake in BioCryst Pharmaceuticals during the first quarter valued at about $62,000. Family Legacy Financial Solutions LLC acquired a new position in shares of BioCryst Pharmaceuticals in the second quarter worth about $72,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of BioCryst Pharmaceuticals in the first quarter worth approximately $79,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.